Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of monoclonal antibodies (mAbs) with the cytotoxic p...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/10/1111 |
| _version_ | 1797513018665336832 |
|---|---|
| author | Charalampos Theocharopoulos Panagiotis-Petros Lialios Michael Samarkos Helen Gogas Dimitrios C. Ziogas |
| author_facet | Charalampos Theocharopoulos Panagiotis-Petros Lialios Michael Samarkos Helen Gogas Dimitrios C. Ziogas |
| author_sort | Charalampos Theocharopoulos |
| collection | DOAJ |
| description | In the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of attached payloads. So far, ten ADCs have been approved by FDA for oncological indications and many others are currently being tested in clinical and preclinical level. This paper summarizes the essential components of ADCs, from their functional principles and structure up to their limitations and resistance mechanisms, focusing on all latest bioengineering breakthroughs such as bispecific mAbs, dual-drug platforms as well as novel linkers and conjugation chemistries. In continuation of our recent review on anticancer implication of ADC’s technology, further insights regarding their potential usage outside of the oncological spectrum are also presented. Better understanding of immunoconjugates could maximize their efficacy and optimize their safety, extending their use in everyday clinical practice. |
| first_indexed | 2024-03-10T06:09:47Z |
| format | Article |
| id | doaj.art-ba7cd38f77ea4666a0fb97b6efb606d7 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T06:09:47Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-ba7cd38f77ea4666a0fb97b6efb606d72023-11-22T20:15:18ZengMDPI AGVaccines2076-393X2021-09-01910111110.3390/vaccines9101111Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and BeyondCharalampos Theocharopoulos0Panagiotis-Petros Lialios1Michael Samarkos2Helen Gogas3Dimitrios C. Ziogas4First Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceFirst Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, 115 27 Athens, GreeceIn the era of precision medicine, antibody-based therapeutics are rapidly enriched with emerging advances and new proof-of-concept formats. In this context, antibody-drug conjugates (ADCs) have evolved to merge the high selectivity and specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of attached payloads. So far, ten ADCs have been approved by FDA for oncological indications and many others are currently being tested in clinical and preclinical level. This paper summarizes the essential components of ADCs, from their functional principles and structure up to their limitations and resistance mechanisms, focusing on all latest bioengineering breakthroughs such as bispecific mAbs, dual-drug platforms as well as novel linkers and conjugation chemistries. In continuation of our recent review on anticancer implication of ADC’s technology, further insights regarding their potential usage outside of the oncological spectrum are also presented. Better understanding of immunoconjugates could maximize their efficacy and optimize their safety, extending their use in everyday clinical practice.https://www.mdpi.com/2076-393X/9/10/1111antibody-drug conjugatesimmunoconjugatesbispecific antibodiesdual-drug ADCstargeted therapy |
| spellingShingle | Charalampos Theocharopoulos Panagiotis-Petros Lialios Michael Samarkos Helen Gogas Dimitrios C. Ziogas Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond Vaccines antibody-drug conjugates immunoconjugates bispecific antibodies dual-drug ADCs targeted therapy |
| title | Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond |
| title_full | Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond |
| title_fullStr | Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond |
| title_full_unstemmed | Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond |
| title_short | Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond |
| title_sort | antibody drug conjugates functional principles and applications in oncology and beyond |
| topic | antibody-drug conjugates immunoconjugates bispecific antibodies dual-drug ADCs targeted therapy |
| url | https://www.mdpi.com/2076-393X/9/10/1111 |
| work_keys_str_mv | AT charalampostheocharopoulos antibodydrugconjugatesfunctionalprinciplesandapplicationsinoncologyandbeyond AT panagiotispetroslialios antibodydrugconjugatesfunctionalprinciplesandapplicationsinoncologyandbeyond AT michaelsamarkos antibodydrugconjugatesfunctionalprinciplesandapplicationsinoncologyandbeyond AT helengogas antibodydrugconjugatesfunctionalprinciplesandapplicationsinoncologyandbeyond AT dimitrioscziogas antibodydrugconjugatesfunctionalprinciplesandapplicationsinoncologyandbeyond |